Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire highlights latest developments from growing research pipeline

Shire highlights latest developments from growing research pipeline

11th December 2014

Shire has held a Research and Development Day for the investment community, during which it provided a discussion of its latest pipeline developments and growth prospects.

Its innovative pipeline is expected to contribute $3 billion (1.92 billion pounds) in product sales by 2020, with a number of significant clinical milestones anticipated over the next 18 months.

The firm recently received fast track designation from US regulators for SHP607, its new treatment for preventing retinopathy of prematurity, with further progress for therapies such as Lifitegrast, SHP625, SHP626 and Vyvanse expected soon.

Additionally, Shire announced a new collaboration with Cystic Fibrosis Foundation Therapeutics to support its promising Messenger RNA Technology platform for cystic fibrosis.

Dr Flemming Ornskov, the company's chief executive officer, said: "Shire's clear and focused strategy has enabled us to transform our pipeline with 22 programmes in the clinic, the most in Shire's history."

The organisation is once again focused on continuing its momentum as a standalone business, following its mutual decision not to move ahead with a planned merger with AbbVie in October.ADNFCR-8000103-ID-801765380-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.